ClinicalTrials.gg
CompletedNCT01796301STRUCTUREUpdated Nov 29, 2022Results posted

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

A Phase 3 interventional study of Romozosumab and Teriparatide in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 50 sites in 11 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
436
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.

Enrollment
3rd of 12
436 · median 268
Started
2013
with 1 other
Phase 3
6 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
9 of 12
Amgen

Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 4th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing romosozumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were previously treated with bisphosphonate therapy.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Postmenopausal Osteoporosis
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women, aged ≥ 55 to ≤ 90.
  • Received oral bisphosphonate therapy for at least 3 years immediately prior to screening
  • BMD T-score ≤ -2.50 at the lumbar spine, total hip or femoral neck
  • History of nonvertebral fracture after age 50, or vertebral fracture.

Exclusion criteria

Exclusion Criteria:

  • Use of other agents affecting bone metabolism including Strontium ranelate, fluoride (for osteoporosis), odanacatib (MK-0822) or any other cathepsin K inhibitor, IV bisphosphonates, denosumab, teriparatide (TPTD) or any parathyroid hormone (PTH) analogs, Systemic oral or transdermal estrogen, selective estrogen receptor modulators (SERMs), activated vitamin D3, vitamin K2, calcitonin, tibolone, cinacalcet, systemic glucocorticosteroids:
  • History of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of study results, such as sclerosteosis, Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome.
  • Vitamin D insufficiency, defined as 25 (OH) vitamin D levels \< 20 ng/mL, as determined by the central laboratory.
  • Current hyper- or hypocalcemia
  • Current, uncontrolled hyper- or hypothyroidism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
436 participants (actual)

Study arms

  • Experimental
    Romosozumab

    Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.

    Drug: Romozosumab

  • Active comparator
    Teriparatide

    Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.

    Drug: Teriparatide

Interventions

  • Administered by subcutaneous injection once a month.

    Also known as: AMG 785

  • Administered by subcutaneous injection once a day.

    Also known as: Forteo, Forsteo

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)

    Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA). Percent change from baseline through month 12 is the average of the treatment effect at months 6 and 12.

    Time frame: Baseline, month 6 and month 12

Secondary outcomes

  1. Percent Change From Baseline in Total Hip BMD at Month 6

    Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline and month 6

  2. Percent Change From Baseline in Total Hip BMD at Month 12

    Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline and month 12

  3. Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6

    Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.

    Time frame: Baseline and month 6

  4. Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12

    Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.

    Time frame: Baseline and month 12

  5. Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6

    Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.

    Time frame: Baseline and month 6

  6. Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12

    Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.

    Time frame: Baseline and month 12

  7. Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6

    Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.

    Time frame: Baseline and month 6

  8. Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12

    Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.

    Time frame: Baseline and month 12

  9. Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6

    Total hip integral BMC was measured using quantitative computed tomography (QCT).

    Time frame: Baseline and month 6

  10. Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 12

    Total hip integral BMC was measured using quantitative computed tomography (QCT).

    Time frame: Baseline and month 12

  11. Percent Change From Baseline in Femoral Neck BMD at Month 6

    Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline and month 6

  12. Percent Change From Baseline in Femoral Neck BMD at Month 12

    Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline and month 12

  13. Percent Change From Baseline in Lumbar Spine BMD at Month 6

    Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline and month 6

  14. Percent Change From Baseline in Lumbar Spine BMD at Month 12

    Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline and month 12

07

Results

Posted Nov 8, 2018

Participant flow

The study was conducted at 46 sites in North America, Latin America, and Europe. Participants were enrolled from 31 January 2013 to 29 April 2014.

Participant flow — Overall Study
MilestoneTeriparatideRomosozumab
Started218218
Received treatment214218
Completed200198
Not completed1820
Withdrew: Withdrawal by subject1515
Withdrew: Lost to follow-up33
Withdrew: Death01
Withdrew: Decision by sponsor01

Outcome measures

PrimaryPercent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)

Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA). Percent change from baseline through month 12 is the average of the treatment effect at months 6 and 12.

Time frame:
Baseline, month 6 and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)
percent changeTeriparatideRomosozumab
Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)-0.6 ± 0.22.6 ± 0.2
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.2 · 95% CI 2.7 to 3.8
SecondaryPercent Change From Baseline in Total Hip BMD at Month 6

Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Hip BMD at Month 6
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Total Hip BMD at Month 6-0.8 ± 0.22.3 ± 0.2
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.1 · 95% CI 2.5 to 3.7
SecondaryPercent Change From Baseline in Total Hip BMD at Month 12

Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Hip BMD at Month 12
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Total Hip BMD at Month 12-0.5 ± 0.22.9 ± 0.2
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.4 · 95% CI 2.8 to 4.0
SecondaryPercent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6

Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6-2.7 ± 0.20.7 ± 0.2
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.4 · 95% CI 2.8 to 4.0
SecondaryPercent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12

Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12-3.6 ± 0.31.1 ± 0.3
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 4.6 · 95% CI 3.9 to 5.3
SecondaryPercent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6

Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6-0.8 ± 0.22.3 ± 0.2
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.1 · 95% CI 2.5 to 3.6
SecondaryPercent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12

Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12-0.2 ± 0.23.4 ± 0.2
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.6 · 95% CI 2.9 to 4.2
SecondaryPercent Change From Baseline in Estimated Strength at the Total Hip at Month 6

Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6-1.0 ± 0.22.1 ± 0.2
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.1 · 95% CI 2.4 to 3.8
SecondaryPercent Change From Baseline in Estimated Strength at the Total Hip at Month 12

Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12-0.7 ± 0.42.5 ± 0.4
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.2 · 95% CI 2.1 to 4.3
SecondaryPercent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6

Total hip integral BMC was measured using quantitative computed tomography (QCT).

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6-0.7 ± 0.22.4 ± 0.2
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.1 · 95% CI 2.6 to 3.6
SecondaryPercent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 12

Total hip integral BMC was measured using quantitative computed tomography (QCT).

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 12
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 120.0 ± 0.23.6 ± 0.2
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.6 · 95% CI 2.9 to 4.2
SecondaryPercent Change From Baseline in Femoral Neck BMD at Month 6

Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Femoral Neck BMD at Month 6
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Femoral Neck BMD at Month 6-1.1 ± 0.32.1 ± 0.3
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.2 · 95% CI 2.5 to 3.9
SecondaryPercent Change From Baseline in Femoral Neck BMD at Month 12

Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Femoral Neck BMD at Month 12
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Femoral Neck BMD at Month 12-0.2 ± 0.33.2 ± 0.3
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.4 · 95% CI 2.6 to 4.2
SecondaryPercent Change From Baseline in Lumbar Spine BMD at Month 6

Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lumbar Spine BMD at Month 6
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Lumbar Spine BMD at Month 63.5 ± 0.37.2 ± 0.3
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 3.8 · 95% CI 2.9 to 4.6
SecondaryPercent Change From Baseline in Lumbar Spine BMD at Month 12

Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lumbar Spine BMD at Month 12
percent changeTeriparatideRomosozumab
Percent Change From Baseline in Lumbar Spine BMD at Month 125.4 ± 0.49.8 ± 0.4
Statistical analysis
  • Teriparatide vs Romosozumab · Linear mixed effects repeated measures · p = < 0.0001 · Treatment difference: 4.4 · 95% CI 3.4 to 5.4

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teriparatide—23/214 (10.7%)76/214 (35.5%)
Romosozumab—17/218 (7.8%)79/218 (36.2%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventTeriparatideRomosozumab
Abdominal painGastrointestinal disorders2/2140/218
PneumoniaInfections and infestations2/2141/218
Atrial fibrillationCardiac disorders0/2142/218
Arrhythmia supraventricularCardiac disorders1/2140/218
Sinus bradycardiaCardiac disorders1/2140/218
VertigoEar and labyrinth disorders1/2140/218
DiarrhoeaGastrointestinal disorders1/2140/218
Gastrointestinal haemorrhageGastrointestinal disorders1/2140/218
Large intestinal ulcerGastrointestinal disorders1/2140/218
Small intestinal obstructionGastrointestinal disorders1/2140/218
Most frequent other events
Most frequent other events
EventTeriparatideRomosozumab
NasopharyngitisInfections and infestations22/21428/218
HypercalcaemiaMetabolism and nutrition disorders22/2142/218
ArthralgiaMusculoskeletal and connective tissue disorders13/21422/218
Back painMusculoskeletal and connective tissue disorders12/21419/218
HeadacheNervous system disorders9/21414/218
FallInjury, poisoning and procedural complications5/21412/218
Upper respiratory tract infectionInfections and infestations9/21411/218
Musculoskeletal painMusculoskeletal and connective tissue disorders5/21411/218
Pain in extremityMusculoskeletal and connective tissue disorders4/21411/218

Baseline characteristics

Age, Continuous
Age, Continuous(years)TeriparatideRomosozumabTotal
Mean71.2 ± 7.771.8 ± 7.471.5 ± 7.5
Age, Customized
Age, Customized(Participants)TeriparatideRomosozumabTotal
< 65 years485098
≥ 65 to < 75 years9683179
≥ 75 years7485159
Sex: Female, Male
Sex: Female, Male(Participants)TeriparatideRomosozumabTotal
Female218218436
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TeriparatideRomosozumabTotal
White196191387
Other182341
American Indian or Alaska Native145
Asian202
Multiple101
Prior Fracture
Prior Fracture(Participants)TeriparatideRomosozumabTotal
Yes217218435
No101
Lumbar Spine BMD T-score
Lumbar Spine BMD T-score(T-score)TeriparatideRomosozumabTotal
Mean-2.87 ± 1.04-2.83 ± 1.10-2.85 ± 1.07
Total Hip BMD T-score
Total Hip BMD T-score(T-score)TeriparatideRomosozumabTotal
Mean-2.21 ± 0.72-2.27 ± 0.75-2.24 ± 0.74
Femoral Neck BMD T-score
Femoral Neck BMD T-score(T-score)TeriparatideRomosozumabTotal
Mean-2.43 ± 0.66-2.49 ± 0.67-2.46 ± 0.66

1 further baseline measures are reported on the registry.

08

Study locations

50 sites
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02131, United States
  • Research Site
    Detroit, Michigan 48236, United States
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1012AAR, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1128AAF, Argentina
  • Research Site
    Cordoba, Córdoba X5000BNB, Argentina
  • Research Site
    Genk, 3600, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liege 1, 4000, Belgium
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Vancouver, British Columbia V6H 3X8, Canada
  • Research Site
    Toronto, Ontario M5C 2T2, Canada
  • Research Site
    Toronto, Ontario M5G 2C4, Canada
  • Research Site
    Quebec, G1V 3M7, Canada
  • Research Site
    Medellin, Antioquia, Colombia
  • Research Site
    Barranquilla, Atlántico 08001000, Colombia
  • Research Site
    Brno, 602 00, Czechia
  • Research Site
    Ostrava 1, 702 00, Czechia
  • Research Site
    Plzen, 305 99, Czechia
  • Research Site
    Praha 11 - Chodov, 148 00, Czechia
  • Research Site
    Uherske Hradiste, 686 01, Czechia
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Aarhus C, 8000, Denmark
  • Research Site
    Ballerup, 2750, Denmark
  • Research Site
    Esbjerg, 6700, Denmark
  • Research Site
    Hillerød, 3400, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    Odense, 5000, Denmark
  • Research Site
    Budapest, 1036, Hungary
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1123, Hungary
  • Research Site
    Gdynia, 81-384, Poland
  • Research Site
    Katowice, 40-040, Poland
  • Research Site
    Warszawa, 01-192, Poland
  • Research Site
    Wroclaw, 50-088, Poland
  • Research Site
    Granada, Andalucía 18012, Spain
  • Research Site
    Barcelona, Cataluña 08041, Spain
  • Research Site
    LHospitalet de Llobregat, Cataluña 08907, Spain
  • Research Site
    Pozuelo de Alarcon, Madrid 28223, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Cardiff, CF14 5GJ, United Kingdom
  • Research Site
    Chorley, PR7 7NA, United Kingdom
  • Research Site
    Liverpool, L22 0LG, United Kingdom
  • Research Site
    Northwood, HA6 2RN, United Kingdom
  • Research Site
    Reading, RG2 0TG, United Kingdom
  • Research Site
    Sidcup, DA14 6LT, United Kingdom
09

References and documents

Publications

  • Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26. PubMed 28755782 ↗
  • Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial. J Bone Miner Metab. 2020 May;38(3):310-315. doi: 10.1007/s00774-019-01057-1. Epub 2019 Nov 9. Erratum In: J Bone Miner Metab. 2020 Jul;38(4):605. doi: 10.1007/s00774-020-01099-w. PubMed 31707465 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in May 2015, 27 months.

Results were first posted in Nov 2018, 3 years 5 months after primary completion. A results delay was requested in Dec 2015.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 27 months is above that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2013
First posted
Feb 21, 2013
StartActual
Jan 31, 2013
Primary completionActual
May 14, 2015
CompletionActual
May 14, 2015
Results delay requested
Dec 19, 2015
Results first posted
Nov 8, 2018
Last update
Nov 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01796301
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 21, 2013
Start date
Jan 31, 2013
Primary completion
May 14, 2015
Completion
May 14, 2015
Results posted
Nov 8, 2018
Last update
Nov 29, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion